Ibrutinib

Indications & Dose:

Treatment of relapsed or refractory mantle cell lymphoma

BY MOUTH

Adult:560 mg once daily, for dose adjustments due to side effects consult product literature

Treatment of chronic lymphocytic leukaemia, in patients who have received at least one prior therapy, or as firstline treatment in patients with deletion or TP53 mutation who are unsuitable for chemo-immunotherapy

Treatment of Waldenstr ms macroglobulinaemia, in patients who have received at least one prior therapy, or

as first-line treatment in patients who are unsuitable for chemo-immunotherapy

BY MOUTH

Adult: 420 mg once daily, for dose adjustments due to side effects consult product literature

Treatment of relapsed or refractory mantle cell lymphoma (reduced dose for patients taking

concomitant moderate or potent CYP3A4 inhibitors)

Treatment of chronic lymphocytic leukaemia, in patients who have received at least one prior therapy, or as firstline treatment in patients with deletion or TP53 mutation who are unsuitable for chemo-immunotherapy

(reduced dose for patients taking concomitant moderate or potent CYP3A4 inhibitors) Treatment of Waldenstr m’s macroglobulinaemia, in patients who have received at least one prior therapy, or as first-line

treatment in patients who are unsuitable for chemoimmunotherapy (reduced dose for patients taking concomitant moderate or potent CYP3A4 inhibitors)

 BY MOUTH

Adult: 140 mg once daily, for dose adjustments due to

side effects consult product literature

Contraindications:

Side Effects:

Cautions:

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: